Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it is projecting Cur18™ to generate over $2.5 million in incremental annual revenue in the United States within the next 12 to 18 months, based on its current commercialization strategy and internal assumptions.

Cur18™ is part of the Company's recently introduced "18 Series," a portfolio of science-based nutraceutical products. It is a curcumin-based dietary supplement formulated with a proprietary ingredient that has been evaluated in published pharmacokinetic and clinical studies and is positioned within the U.S. turmeric/curcumin supplement category.

The Company's projection reflects a phased market entry strategy, initially focused on direct-to-consumer e-commerce channels, with potential expansion into selected retail channels over time. It is based on internal assumptions regarding pricing, expected sales volumes, and the gradual expansion of distribution, and is subject to the continued execution of the Company's commercialization strategy.